Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
EGE
MCID: ESN005
MIFTS: 55

Eosinophilic Gastroenteritis (EGE)

Categories: Gastrointestinal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Eosinophilic Gastroenteritis

About this section

MalaCards integrated aliases for Eosinophilic Gastroenteritis:

Name: Eosinophilic Gastroenteritis 12 74 52 58 54 15 71
Eosinophilic Gastroenterocolitis 52 58
Eosinophilic Enteritis 52 58
Ege 52 58
Eosinophilic Gastroenteropathy 52
Gastroenteritis, Eosinophilic 74
Eosinophilic Esophagitis 52
Eosinophilic Enteropathy 71
Eosinophilic Gastritis 52

Characteristics:

Orphanet epidemiological data:

58
eosinophilic gastroenteritis
Inheritance: Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Disease Ontology 12 DOID:4031
ICD9CM 34 558.41
NCIt 49 C35330
SNOMED-CT 67 359804008
MESH via Orphanet 44 C535952
ICD10 via Orphanet 33 K52.8
UMLS via Orphanet 72 C1262481 C2062326
Orphanet 58 ORPHA2070
UMLS 71 C1262481 C2062326
Sources

Summaries for Eosinophilic Gastroenteritis

About this section
MalaCards based summary : Eosinophilic Gastroenteritis, also known as eosinophilic gastroenterocolitis, is related to omenn syndrome and eosinophilic colitis. An important gene associated with Eosinophilic Gastroenteritis is CCL11 (C-C Motif Chemokine Ligand 11), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Budesonide and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include colon, small intestine and testes, and related phenotypes are eosinophilia and vomiting

Wikipedia : 74 Eosinophilic gastroenteritis (EG) is a rare and heterogeneous condition characterized by patchy or... more...

Sources

Related Diseases for Eosinophilic Gastroenteritis

About this section

Diseases related to Eosinophilic Gastroenteritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 631)
# Related Disease Score Top Affiliating Genes
1 omenn syndrome 31.6 IL5 IL4 CCR6
2 eosinophilic colitis 31.2 RNASE3 PRG2
3 aplastic anemia 31.2 IL4 IL3 CSF3 CSF2 ALB
4 hypereosinophilic syndrome, idiopathic 31.2 IL5 IL3
5 ige responsiveness, atopic 31.1 RNASE3 IL5 IL4
6 diarrhea 30.9 IL5 IL3 CSF3 ALB
7 milk allergy 30.8 RNASE3 IL5 IL4
8 candidiasis 30.7 IL4 CSF2 CCR6
9 food allergy 30.6 RNASE3 IL5 IL4 EPX ALB
10 urticaria 30.5 RNASE3 PRG2 IL5 IL4
11 peritonitis 30.3 IL4 CSF3 ALB
12 chlamydia 30.3 IL5 IL4 CSF2
13 toxocariasis 30.3 RNASE3 IL5 IL4
14 cow milk allergy 30.3 RNASE3 IL5 IL4
15 dermatitis herpetiformis 30.3 IL5 IL4 CCL11
16 allergic bronchopulmonary aspergillosis 30.3 IL5 IL4 EPX
17 peanut allergy 30.2 IL5 IL4 CCR6
18 contact dermatitis 30.1 IL5 IL4 IL33
19 intestinal obstruction 30.1 ATP4A ATP12A ALB
20 allergic rhinitis 30.1 RNASE3 IL5 IL4 EPX CSF2 CCL11
21 proteasome-associated autoinflammatory syndrome 1 30.0 RNASE3 IL5 IL4 CCL11
22 keratoconjunctivitis sicca 30.0 IL4 CCR6 ALB
23 dermatitis 30.0 TSLP IL5 IL4 CCR6 CCL11
24 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 29.9 IL3 CSF3 ALB
25 esophagitis 29.9 TSLP IL5 IL4 IL33 CCL26 CCL11
26 klebsiella pneumonia 29.9 CCR6 ALB
27 stomatitis 29.9 IL4 CSF3 CSF2
28 hypereosinophilic syndrome 29.8 RNASE3 PRG2 IL5 IL4 IL3 EPX
29 duodenal obstruction 29.8 ATP4A ATP12A ALB
30 pollen allergy 29.7 RNASE3 PRG2 IL5 IL3 EPX
31 intestinal perforation 29.7 ATP4A ATP12A ALB
32 cellulitis 29.7 RNASE3 IL5 IL4 CCR6
33 egg allergy 29.7 TSLP IL5 IL4 CCR6
34 chronic eosinophilic pneumonia 29.7 RNASE3 IL5 CSF3 CCL11
35 churg-strauss syndrome 29.6 RNASE3 PRG2 IL5 IL3 CCL26 CCL11
36 essential thrombocythemia 29.6 IL4 IL3 CSF3 CSF2
37 bronchitis 29.6 RNASE3 IL5 IL4 CCL11 ALB
38 neutropenia 29.6 IL3 CSF3 CSF2 ALB
39 thrombocytosis 29.6 IL3 CSF3 CSF2 ALB
40 necrotizing gastritis 29.6 ATP4A ATP12A
41 pneumatosis cystoides intestinalis 29.6 ATP4A ATP12A
42 paralytic ileus 29.5 ATP4A ATP12A ALB
43 meningitis 29.5 IL5 IL4 CSF3 CSF2 ALB
44 peptic esophagitis 29.5 CCL26 ATP4A ATP12A ALB
45 bacterial infectious disease 29.4 IL3 CSF3 CSF2 CCR6
46 intrinsic asthma 29.4 TSLP RNASE3 IL5 IL4 IL3 CSF2
47 dyskinesia of esophagus 29.4 CCL26 ATP4A ATP12A
48 granulomatosis with polyangiitis 29.4 IL5 CCR6 CCL26
49 diphtheria 29.4 IL5 IL4 IL3 CSF2 ALB
50 gastric dilatation 29.3 ATP4A ATP12A

Graphical network of the top 20 diseases related to Eosinophilic Gastroenteritis:



Diseases related to Eosinophilic Gastroenteritis
Sources

Symptoms & Phenotypes for Eosinophilic Gastroenteritis

About this section

Human phenotypes related to Eosinophilic Gastroenteritis:

58 31 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 eosinophilia 58 31 hallmark (90%) Very frequent (99-80%) HP:0001880
2 vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002013
3 dysphagia 58 31 frequent (33%) Frequent (79-30%) HP:0002015
4 anemia 58 31 frequent (33%) Frequent (79-30%) HP:0001903
5 abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002027
6 steatorrhea 58 31 frequent (33%) Frequent (79-30%) HP:0002570
7 hypoalbuminemia 58 31 frequent (33%) Frequent (79-30%) HP:0003073
8 elevated c-reactive protein level 58 31 frequent (33%) Frequent (79-30%) HP:0011227
9 allergic rhinitis 58 31 frequent (33%) Frequent (79-30%) HP:0003193
10 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
11 edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0000969
12 ascites 58 31 occasional (7.5%) Occasional (29-5%) HP:0001541
13 asthma 58 31 occasional (7.5%) Occasional (29-5%) HP:0002099
14 hematochezia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002573
15 elevated erythrocyte sedimentation rate 58 31 occasional (7.5%) Occasional (29-5%) HP:0003565
16 atopic dermatitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001047
17 protein-losing enteropathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002243
18 malabsorption 58 Frequent (79-30%)
19 abnormality of the gastrointestinal tract 58 Frequent (79-30%)
20 diarrhea 58 Frequent (79-30%)
21 leukocytosis 58 Frequent (79-30%)
22 abnormal test result 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Eosinophilic Gastroenteritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 ATP4A CCL11 CCR6 CSF2 CSF3 EPX
2 homeostasis/metabolism MP:0005376 9.9 ALB ATP12A ATP4A CCR6 CSF2 EPX
3 digestive/alimentary MP:0005381 9.87 ALB ATP12A ATP4A IL33 IL4 IL5
4 immune system MP:0005387 9.73 ALB ATP4A CCL11 CCR6 CSF2 CSF3
5 respiratory system MP:0005388 9.17 CCL11 CSF2 IL33 IL4 IL5 PRG2
Sources

Drugs & Therapeutics for Eosinophilic Gastroenteritis

About this section

Drugs for Eosinophilic Gastroenteritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 114)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Budesonide Approved Phase 4 51333-22-3 63006 5281004
2
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
3
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
4
Citalopram Approved Phase 4 59729-33-8 2771
5 Hormone Antagonists Phase 4
6 Hormones Phase 4
7 glucocorticoids Phase 4
8 Soy Bean Phase 4
9 Cromolyn Sodium Phase 4
10 Olive Phase 4
11 Respiratory System Agents Phase 4
12 Anti-Allergic Agents Phase 4
13 Anti-Asthmatic Agents Phase 4
14 Antacids Phase 4
15 Anti-Ulcer Agents Phase 4
16 Gastrointestinal Agents Phase 4
17 Dermatologic Agents Phase 4
18 Bronchodilator Agents Phase 4
19 Anti-Inflammatory Agents Phase 4
20 Proton Pump Inhibitors Phase 4
21 Neurotransmitter Agents Phase 4
22 Antidepressive Agents Phase 4
23 Psychotropic Drugs Phase 4
24 Serotonin Uptake Inhibitors Phase 4
25
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
26
Reslizumab Approved, Investigational Phase 2, Phase 3 241473-69-8
27
Esomeprazole Approved, Investigational Phase 2, Phase 3 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
28 Benralizumab Approved, Investigational Phase 2, Phase 3 1044511-01-4
29
Histamine Approved, Investigational Phase 3 51-45-6 774
30
Ketotifen Approved Phase 3 34580-13-7, 34580-14-8 3827
31 Immunoglobulins Phase 2, Phase 3
32 Antibodies Phase 2, Phase 3
33 Immunoglobulins, Intravenous Phase 2, Phase 3
34 Antibodies, Monoclonal Phase 2, Phase 3
35 Immunoglobulin G Phase 2, Phase 3
36 Histamine Antagonists Phase 3
37 Histamine H1 Antagonists Phase 3
38
Histamine Phosphate Phase 3 51-74-1 65513
39
Omalizumab Approved, Investigational Phase 2 242138-07-4
40
Losartan Approved Phase 2 114798-26-4 3961
41
Angiotensin II Approved, Investigational Phase 2 4474-91-3, 11128-99-7, 68521-88-0 172198
42
Infliximab Approved Phase 2 170277-31-3
43
tannic acid Approved Phase 2 1401-55-4
44
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
45
Famotidine Approved Phase 2 76824-35-6 3325
46
Loratadine Approved, Investigational Phase 2 79794-75-5 3957
47
Bethanechol Approved Phase 2 674-38-4 2370
48
mometasone furoate Approved, Investigational, Vet_approved Phase 2 83919-23-7
49
Trichostatin A Experimental Phase 2 58880-19-6
50 Vasoconstrictor Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 162)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-blind, Placebo-controlled Study of the Use of Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
2 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Completed NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
3 COMPARISON OF TREATMENT FOR PEDIATRIC EOSINOPHILIC ESOPHAGITIS: A RANDOMIZED CLINICAL TRIAL (DIETETIC Versus TOPICAL STEROIDS) Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
4 Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE) Recruiting NCT04149470 Phase 4 Omeprazole 20mg BID
5 Randomized Controlled Trial Comparing Fluticasone Plus Omeprazole With Fluticasone Alone for Eosinophilic Esophagitis Recruiting NCT03781596 Phase 4 Fluticasone;Omeprazole;Placebo oral capsule
6 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
7 Proton Pump Inhibitor (PPI's) and Selective Serotonin Reuptake Inhibitor Therapy (SSRI's) for the Management of Non Cardiac Chest Pain (NCCP) Terminated NCT02825342 Phase 4 Citalopram
8 Effect of Swallowed Fluticasone Propionate on Eosinophilic Esophagitis; A Prospective, Randomized, Placebo-Controlled Trial Completed NCT00266578 Phase 3 Fluticasone Propionate
9 An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Completed NCT00538434 Phase 2, Phase 3
10 Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study Completed NCT02605837 Phase 3 Oral Budesonide Suspension (OBS);Placebo
11 Double-blind, Randomized, Placebo-controlled, Phase III Trial on the Efficacy and Tolerability of a 6-week Treatment With Budesonide Effervescent Tablets vs. Placebo for Induction of Clinico-pathological Remission in Adult Patients With Active Eosinophilic Esophagitis Completed NCT02434029 Phase 3 Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
12 An Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Esophagitis Who Completed Study Res-5-0002 Completed NCT00635089 Phase 3 reslizumab
13 A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE) Completed NCT02736409 Phase 3 Oral Budesonide Suspension (OBS);Placebo
14 Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids Completed NCT02610816 Phase 2, Phase 3 Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)
15 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed NCT00728481 Phase 2, Phase 3 Esomeprazole;Budesonide
16 Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial Completed NCT02778867 Phase 2, Phase 3 Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)
17 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) Recruiting NCT04322604 Phase 3 antolimab (AK002)
18 A Double-Blind, Placebo-controlled Clinical Trial to Evaluate Efficacy of Benralizumab in Subjects With Eosinophilic Gastritis Recruiting NCT03473977 Phase 2, Phase 3
19 A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Antolimab (AK002) in Adult and Adolescent Patients With Active Eosinophilic Esophagitis Recruiting NCT04322708 Phase 2, Phase 3 antolimab (AK002)
20 Fluticasone Propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult and Adolescent Subjects With Eosinophilic Esophagitis Recruiting NCT04281108 Phase 3 APT-1011;Placebo oral tablet
21 A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) Recruiting NCT03633617 Phase 3 Dupilumab;Placebo
22 Double-blind, Placebo-controlled, Cross-over Trial of Ketotifen in Children and Adolescents With Functional Dyspepsia in Association With Duodenal Eosinophilia Recruiting NCT02484248 Phase 3 Ketotifen;Placebo
23 Double-blind, Randomized, Placebo-controlled, Phase III Study on the Efficacy and Tolerability of a 48-week Treatment With Two Different Doses of Budesonide Effervescent Tablets vs. Placebo for Maintenance of Clinico-pathological Remission in Adult Patients With Eosinophilic Esophagitis Active, not recruiting NCT02493335 Phase 3 Budesonide 0.5mg orodispersible tablet twice daily;Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
24 A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE) Active, not recruiting NCT03245840 Phase 3 Budesonide oral suspension
25 A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis Not yet recruiting NCT04394351 Phase 3 Dupilumab;Matching Placebo
26 Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Withdrawn NCT01702701 Phase 3 Montelukast;Fluticasone
27 A Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder. Unknown status NCT01808196 Phase 2 Losartan Potassium
28 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Completed NCT03496571 Phase 2 AK002
29 Pilot Study of Omalizumab in Eosinophilic Gastroenteritis Completed NCT00084097 Phase 2 Omalizumab
30 A Phase I/II Study of the Effect of Intravenous Anti-IL-5 (Mepolizumab) SB 240563 on the Outcome and Management of Hypereosinophilic Syndromes Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
31 A Double Blinded, Randomized Trial of Swallowed 1760mcg Fluticasone Propionate Versus Placebo in the Treatment of Eosinophilic Esophagitis Completed NCT00426283 Phase 2 Flovent
32 A Randomized, Placebo-controlled, Double-blind, Single-centre Proof-of-concept Study of OC000459 in Adult Patients With Active Eosinophilic Esophagitis Completed NCT01056783 Phase 2 OC000459;Placebo
33 A Double Blinded Randomized Placebo-controlled Trial of Intravenous QAX576 in the Treatment of Eosinophilic Esophagitis (EoE) Completed NCT01022970 Phase 2 QAX576 placebo;QAX576
34 A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis Completed NCT02098473 Phase 2 RPC4046;Placebo
35 Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis, a Randomized Clinical Trial Completed NCT00638456 Phase 2 Budesonide plus Prevacid;placebo plus Prevacid
36 Oral Viscous Budesonide Suspension (MB-7) in Subjects With Eosinophilic Esophagitis: A Randomized, Placebo-Controlled, Dose-Ranging Study in Children and Adolescents Completed NCT00762073 Phase 2 budesonide;placebo
37 A Double, Blind Placebo-controlled, Randomized Trial to Study Efficacy and Safety of the Viaskin Milk for Treating Milk Induced Eosinophilic Esophagitis in Children Completed NCT02579876 Phase 2 Viaskin Milk 500 mcg;Viaskin Placebo
38 A Randomized, Double-blind, Parallel Group Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in Pediatric Subjects With Eosinophilic Esophagitis, Aged 2 to 17 Years (Study MEE103219) Completed NCT00358449 Phase 2 mepolizumab
39 A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis Completed NCT02379052 Phase 2 Dupilumab;Placebo
40 Double-blind, Double-dummy, Randomized, Placebo-controlled, Phase IIa Study on the Efficacy and Tolerability of a 14-day Treatment With Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Patients With Eosinophilic Esophagitis Completed NCT02280616 Phase 2 low dose budesonide tablet;high dose budesonide tablet;high dose budesonide suspension;Placebo
41 Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11-40 Years of Age)With Eosinophilic Esophagitis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open Label Extension Completed NCT01642212 Phase 2 Oral Budesonide Suspension (MB-9);Placebo
42 A Preliminary Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder Completed NCT03029091 Phase 2 Losartan Potassium
43 Budesonide for Eosinophilic Esophagitis: a Randomized, Placebo-controlled, Double-blind Treatment Study Completed NCT00271349 Phase 2 Budesonide
44 A Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, in Subjects With Eosinophilic Esophagitis (EoE) Completed NCT01386112 Phase 1, Phase 2 EUR-1100;placebo
45 A Randomized Placebo-controlled Trial of Swallowed Fluticasone in Treatment of Eosinophilic Esophagitis Completed NCT00275561 Phase 2 Fluticasone;Placebo
46 Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis Completed NCT00123656 Phase 2 esomeprazole;fluticasone
47 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab Completed NCT00123630 Phase 2 omalizumab;Placebo
48 Phase 2 Proof-of-Concept Study to Analyze the Efficacy of in TNF-Alpha Blockade in Adult Patients With Severe, Corticosteroid-Dependent Eosinophilic Esophagitis Completed NCT00523354 Phase 2 Infliximab
49 A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Provide a Preliminary Evaluation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Intravenous Anti-human Interleukin-5 (Mepolizumab, 750mg and 1500mg) in the Treatment of Eosinophilic Oesophagitis in Adults Completed NCT00274703 Phase 2 mepolizumab
50 Anti-IL-5 Therapy in Bullous Pemphigoid. Randomized, Placebo-controlled, Double-blind Study Evaluating the Effect of Anti-IL-5 Therapy in Patients With Bullous Pemphigoid. Completed NCT01705795 Phase 2 Mepolizumab (a-IL-5 antibody);Placebo

Search NIH Clinical Center for Eosinophilic Gastroenteritis

Sources

Genetic Tests for Eosinophilic Gastroenteritis

About this section
Sources

Anatomical Context for Eosinophilic Gastroenteritis

About this section

MalaCards organs/tissues related to Eosinophilic Gastroenteritis:

40
Colon, Small Intestine, Testes, Bone, Liver, T Cells, Bone Marrow
Sources

Publications for Eosinophilic Gastroenteritis

About this section

Articles related to Eosinophilic Gastroenteritis:

(show top 50) (show all 852)
# Title Authors PMID Year
1
Gastrointestinal manifestations of food allergies in pediatric patients. 61 54
16207693 2005
2
Eosinophilic gastroenteritis. 54 61
15833687 2005
3
[A case of eosinophilic gastroenteritis: observation of serum IL-5 and sIL-2R levels before and after remission]. 54 61
15187490 2004
4
Allergic eosinophilic gastroenteritis in a child with Crohn's disease. 54 61
15301307 2004
5
Human intestinal mast cells produce IL-5 in vitro upon IgE receptor cross-linking and in vivo in the course of intestinal inflammatory disease. 54 61
10359103 1999
6
Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. 54 61
8608886 1996
7
Milk-induced eczema is associated with the expansion of T cells expressing cutaneous lymphocyte antigen. 54 61
7532192 1995
8
Evidence for an abnormal profile of interleukin-4 (IL-4), IL-5, and gamma-interferon (gamma-IFN) in peripheral blood T cells from patients with allergic eosinophilic gastroenteritis. 61 54
7814459 1994
9
IgE antibodies against bovine serum albumin in a case of eosinophilic gastroenteritis. 61 54
8238812 1993
10
Interleukin-5 in eosinophilic gastroenteritis. 54 61
1380204 1992
11
Multiple ulcerations and perforation in the small intestine after steroid treatment in eosinophilic granulomatosis with polyangiitis: a case report and literature review. 61
32151788 2020
12
Association Between Endoscopic and Histologic Findings in a Multicenter Retrospective Cohort of Patients with Non-esophageal Eosinophilic Gastrointestinal Disorders. 61
31773359 2020
13
Efficacy of a Short-term Six-food Elimination Diet and Reintroduction Therapy in Pediatric Eosinophilic Gastroenteritis. 61
32101833 2020
14
Eosinophilic gastroenteritis: epidemiology, diagnosis, and treatment. 61
32073433 2020
15
Eosinophilic Gastroenteritis-associated Duodenal Ulcer Successfully Treated with Crushed Budesonide. 61
32536650 2020
16
Eosinophilic gastroenteritis and graft-versus-host disease induced by transmission of Norovirus with fecal microbiota transplant. 61
32574415 2020
17
Nationwide Multicenter Study of Eosinophilic Esophagitis in Korean Children. 61
32483544 2020
18
Targeted Therapies for Eosinophilic Gastrointestinal Disorders. 61
32472465 2020
19
Eosinophilic gastroenteritis in pregnancy: A review of the literature. 61
32199294 2020
20
Eosinophilic gastroenteritis in small intestine in a child in a remote medical centre required surgery. 61
32474378 2020
21
Abnormal thymic stromal lymphopoietin expression in the gastrointestinal mucosa of patients with eosinophilic gastroenteritis. 61
30763528 2020
22
Eosinophilic gastroenteritis with multiple serous membrane effusion as the first sign: a case report and literature review. 61
32321384 2020
23
Appearance of Gastric Polypoid Lesions in Eosinophilic Gastroenteritis. 61
31232829 2020
24
Eosinophilic ascites: an unusual manifestation of eosinophilic gastroenteritis. 61
31989248 2020
25
Eosinophilic Granulomatosis with Polyangiitis Initially Diagnosed as Eosinophilic Gastroenteritis. 61
31875634 2020
26
Myenteric networks of interstitial cells of Cajal are reduced in horses with inflammatory bowel disease. 61
31397916 2020
27
Eosinophils, a Jack of All Trades in Immunity: Therapeutic Approaches for Correcting their Functional Disorders. 61
32148205 2020
28
Ascites: an unusual presentation of eosinophilic gastroenteritis in a child. 61
32178592 2020
29
Eosinophilic gastroenteritis developed after remission of cow's milk allergy. 61
32011798 2020
30
Upper Gastrointestinal Bleed in a Young Male- A Rare Presentation of Eosinophilic Gastroenteritis. 61
32219053 2020
31
[A CASE OF EOSINOPHILIC GASTROENTERITIS FOUND BY PICA DURING ORAL IMMUNOTHERAPY]. 61
32188824 2020
32
Eosinophilic gastroenteritis with persistent abdominal pain: a case report. 61
32015781 2020
33
Neonatal eosinophilic gastroenteritis mimicking hypertrophic pyloric stenosis. 61
31997530 2020
34
Eosinophilic pancreatitis: a rare or unexplored disease entity? 61
32215125 2020
35
Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report. 61
32336975 2020
36
Eosinophilic pancreatitis versus pancreatitis associated with eosinophilic gastroenteritis - a systematic review regarding clinical features and diagnosis. 61
31120859 2019
37
Eosinophilic gastroenteritis presenting as achalasia cardia and responding to botulinum injection and therapy directed against eosinophilic esophagitis. 61
31950436 2019
38
Eosinophilic gastrointestinal diseases - Pathogenesis, diagnosis, and treatment. 61
31000445 2019
39
Eosinophilic esophagitis: novel concepts regarding pathogenesis and clinical manifestations. 61
31342146 2019
40
Eosinophilic Gastrointestinal Disorders. 61
30903439 2019
41
Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis. 61
31465299 2019
42
Eosinophilic Gastrointestinal Diseases in Children: A Practical Review 61
31642786 2019
43
Retrospective study of budesonide in children with eosinophilic gastroenteritis. 61
31141816 2019
44
A man with abdominal pain and eosinophilia : tissue is the issue. 61
31950810 2019
45
Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and Vedolizumab. 61
30982212 2019
46
Endoscopic Features and Diagnostic Procedures of Eosinophilic Gastroenteritis. 61
30996166 2019
47
Modified oral enteric-coated budesonide regimens to treat pediatric eosinophilic gastroenteritis, a single center experience. 61
30763733 2019
48
Causes of eosinophilic ascites - A systematic review. 61
30864403 2019
49
Abdominal ascites in children as the presentation of eosinophilic gastroenteritis: A surgeon's perspective. 61
30528318 2019
50
Eosinophilic Gastroenteritis Presenting With Gastric Perforation. 61
29366927 2019
Sources

Variations for Eosinophilic Gastroenteritis

About this section
Sources

Expression for Eosinophilic Gastroenteritis

About this section
Search GEO for disease gene expression data for Eosinophilic Gastroenteritis.
Sources

Pathways for Eosinophilic Gastroenteritis

About this section

Pathways related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.91 RNASE3 PRG2 IL5 IL4 IL33 IL3
2
ERK Signaling 63
Show member pathways
 13.71 PRG2 IL5 IL4 IL3 CSF3 CSF2
3
PEDF Induced Signaling 63
Show member pathways
 13.56 TSLP IL5 IL4 IL33 IL3 CSF3
4
Akt Signaling 63
Show member pathways
 13.32 IL5 IL4 IL3 CSF3 CSF2 CCR6
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.25 IL5 IL4 IL33 IL3 CSF3 CSF2
6
PAK Pathway 63
Show member pathways
 13.22 IL5 IL4 IL3 CSF3 CSF2 CCR6
7
Allograft rejection 1 36
Show member pathways
 12.72 RNASE3 PRG2 IL5 IL4 IL3 EPX
8
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.45 IL5 IL4 IL3 CSF2
9
JAK-STAT signaling pathway 36
Show member pathways
 12.37 TSLP IL5 IL4 IL3 CSF3 CSF2
10
IL-17 Family Signaling Pathways 64
Show member pathways
 12.29 IL5 IL4 CSF3 CSF2 CCL11
11
Hematopoietic Stem Cells and Lineage-specific Markers 64
11.87 IL5 IL4 IL3 CSF3 CSF2
12
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.72 IL5 IL4 IL3 CSF2
13
Hematopoietic cell lineage 36
11.72 IL5 IL4 IL3 CSF3 CSF2
14
Glucocorticoid receptor regulatory network 1
11.69 IL5 IL4 CSF2
15
IL4-mediated signaling events 1
11.61 IL5 IL4 CCL26 CCL11
16
Innate Lymphoid Cells Differentiation 64
11.56 TSLP IL5 IL4 IL33 CCR6
17
Interleukin-10 signaling 65
11.46 IL4 CSF3 CSF2
18
Hematopoietic Stem Cell Differentiation 1
11.46 IL5 IL3 CSF3 CSF2
19
Th2 Differentiation 64
11.42 IL5 IL4 IL33 CCL11
20
Development and heterogeneity of the ILC family 1
11.17 TSLP IL5 IL4 IL33
21
Lung fibrosis 1
11.15 IL5 IL4 CSF3 CSF2 CCL11
22
IL-9 Signaling and its Primary Biological Effects in Different Immune Cell Types 64
10.69 IL5 IL4
23
G-protein signaling_Rap2B regulation pathway 22
10.66 PRG2 IL5 IL4 IL3 CSF3 CSF2
24
Cytokines and Inflammatory Response 1
10.48 IL5 IL4 IL3 CSF3 CSF2
Sources

GO Terms for Eosinophilic Gastroenteritis

About this section

Cellular components related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 TSLP RNASE3 PRG2 IL5 IL4 IL33
2 extracellular space GO:0005615 9.44 TSLP RNASE3 IL5 IL4 IL33 IL3

Biological processes related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.8 TSLP IL5 IL4 IL3 CSF3 CSF2
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.67 IL5 IL3 CSF3
3 chemokine-mediated signaling pathway GO:0070098 9.61 CCR6 CCL26 CCL11
4 myeloid dendritic cell differentiation GO:0043011 9.58 IL4 CSF2
5 cellular sodium ion homeostasis GO:0006883 9.57 ATP4A ATP12A
6 dendritic cell differentiation GO:0097028 9.56 IL4 CSF2
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.56 TSLP IL4 IL3 CSF2
8 sodium ion export across plasma membrane GO:0036376 9.55 ATP4A ATP12A
9 cellular potassium ion homeostasis GO:0030007 9.54 ATP4A ATP12A
10 positive regulation of actin filament polymerization GO:0030838 9.54 CSF3 CCL26 CCL11
11 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.52 ATP4A ATP12A
12 macrophage activation GO:0042116 9.51 IL4 CSF2
13 positive regulation of podosome assembly GO:0071803 9.48 IL5 CSF2
14 positive regulation of immunoglobulin secretion GO:0051024 9.46 IL5 IL33
15 cytokine-mediated signaling pathway GO:0019221 9.43 IL5 IL4 IL3 CSF3 CSF2 CCL11
16 positive regulation of interleukin-5 production GO:0032754 9.4 TSLP IL33
17 positive regulation of interleukin-13 production GO:0032736 9.33 TSLP IL4 IL33
18 immune response GO:0006955 9.28 PRG2 IL5 IL4 IL3 CSF3 CSF2

Molecular functions related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 9.37 ATP4A ATP12A
2 growth factor activity GO:0008083 9.35 IL5 IL4 IL3 CSF3 CSF2
3 potassium-transporting ATPase activity GO:0008556 9.32 ATP4A ATP12A
4 cytokine activity GO:0005125 9.28 TSLP IL5 IL4 IL33 IL3 CSF3
5 CCR3 chemokine receptor binding GO:0031728 9.26 CCL26 CCL11
6 potassium:proton exchanging ATPase activity GO:0008900 9.16 ATP4A ATP12A
Sources

Sources for Eosinophilic Gastroenteritis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....